Cannabix Technologies delivers Marijuana Breath Test Hardware to Omega Laboratories Inc.
Cannabix Technologies (OTC:BLOZF) has delivered multiple Marijuana Breath Test (MBT) units to Omega Laboratories in Ohio, marking a significant step in their commercialization efforts. The technology includes proprietary Breath Collection Units (BCU) and Breath Cartridges (BC) designed to detect recent cannabis use through delta-9-tetrahydrocannabinol (螖9-THC) detection.
The initial delivery comprises 200 Breath Cartridges and several BCUs. The companies are collaborating on manufacturing, marketing, distribution, and logistics for the MBT. Omega Laboratories, an international leader in forensic drug testing with ISO/IEC 17025 accreditation, has already delivered a Validation Packet for their Laboratory Developed Test Method to test delta-9 THC analytes.
Cannabix Technologies (OTC:BLOZF) ha consegnato diverse unit脿 del Marijuana Breath Test (MBT) a Omega Laboratories in Ohio, segnando un passo importante nella commercializzazione del prodotto. La tecnologia comprende i proprietari Breath Collection Units (BCU) e Breath Cartridges (BC) progettati per rilevare l'uso recente di cannabis tramite il rilevamento del delta-9-tetraidrocannabinolo (螖9-THC).
La consegna iniziale comprende 200 Breath Cartridges e diverse BCU. Le due societ脿 collaboreranno alla produzione, al marketing, alla distribuzione e alla logistica per il MBT. Omega Laboratories, leader internazionale nei test forensi sulle droghe con accreditamento ISO/IEC 17025, ha gi脿 fornito un Validation Packet per il loro metodo di test di laboratorio sviluppato per analizzare i composti delta-9 THC.
Cannabix Technologies (OTC:BLOZF) ha entregado varias unidades del Marijuana Breath Test (MBT) a Omega Laboratories en Ohio, marcando un avance significativo en sus esfuerzos de comercializaci贸n. La tecnolog铆a incluye los propietarios Breath Collection Units (BCU) y Breath Cartridges (BC) dise帽ados para detectar el consumo reciente de cannabis mediante la detecci贸n de delta-9-tetrahidrocannabinol (螖9-THC).
La entrega inicial consiste en 200 Breath Cartridges y varias BCU. Las empresas colaborar谩n en la fabricaci贸n, comercializaci贸n, distribuci贸n y log铆stica del MBT. Omega Laboratories, l铆der internacional en pruebas forenses de drogas con acreditaci贸n ISO/IEC 17025, ya ha entregado un Validation Packet para su m茅todo de prueba desarrollado en laboratorio para analizar los analitos de delta-9 THC.
Cannabix Technologies (OTC:BLOZF)電� 鞓ろ晿鞚挫槫鞚� Omega Laboratories鞐� 雼れ垬鞚� 毵堧Μ頇旊倶 順疙潯 瓴�靷赴(MBT) 鞛レ箻毳� 瓿店笁頃橃棳 靸侅毄頇旍棎 欷戩殧頃� 歆勳爠鞚� 鞚措（鞐堨姷雼堧嫟. 鞚� 旮办垹鞐愲姅 斓滉芳 雽�毵堨磮 靷毄鞚� 螖9-韰岉姼霛柬晿鞚措摐搿滌垢雮橂箘雴�(螖9-THC) 瓴�於滌潉 韱淀暣 臧愳頃橂弰搿� 靹り硠霅� 霃呾爯 Breath Collection Units(BCU) 氚� Breath Cartridges(BC)臧� 韽暔霅╇媹雼�.
齑堦赴 氚办啞鞐愲姅 200臧滌潣 Breath Cartridges鞕� 鞐煬 雽�鞚� BCU臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞏戩偓電� MBT鞚� 鞝滌“, 毵堨紑韺�, 鞙犿喌 氚� 氍茧毳� 瓿惦彊鞙茧 歆勴枆頃� 鞓堨爼鞛呺媹雼�. ISO/IEC 17025 鞚胳鞚� 氤挫湢頃� 韽爩鞁� 鞎诫 瓴�靷� 攵勳暭鞚� 甑牅鞝� 靹犽憪欤检瀽鞚� Omega Laboratories電� 鞚措 螖9-THC 攵勳劃鞚� 鞙勴暅 鞐瓣惮靻� 鞛愳泊 臧滊皽 韰岇姢韸� 氚╇矔鞚� 鞙犿毃靹� 瓴�歃� 韺偆歆�(Validation Packet)毳� 鞝滌稖頄堨姷雼堧嫟.
Cannabix Technologies (OTC:BLOZF) a livr茅 plusieurs unit茅s du Marijuana Breath Test (MBT) 脿 Omega Laboratories dans l'Ohio, marquant une 茅tape importante dans leurs efforts de commercialisation. La technologie comprend des Breath Collection Units (BCU) et Breath Cartridges (BC) propri茅taires con莽us pour d茅tecter une consommation r茅cente de cannabis via la d茅tection du delta-9-t茅trahydrocannabinol (螖9-THC).
La livraison initiale comprend 200 Breath Cartridges et plusieurs BCU. Les soci茅t茅s collaboreront 脿 la fabrication, au marketing, 脿 la distribution et 脿 la logistique du MBT. Omega Laboratories, leader international des tests de drogues m茅dico-l茅gaux avec accr茅ditation ISO/IEC 17025, a d茅j脿 fourni un Validation Packet pour leur m茅thode de test d茅velopp茅e en laboratoire afin d'analyser les analytes delta-9 THC.
Cannabix Technologies (OTC:BLOZF) hat mehrere Marijuana Breath Test (MBT)-Einheiten an Omega Laboratories in Ohio geliefert und damit einen bedeutenden Schritt in Richtung Kommerzialisierung gemacht. Die Technologie umfasst propriet盲re Breath Collection Units (BCU) und Breath Cartridges (BC), die f眉r den Nachweis k眉rzlicher Cannabiskonsumation durch Erkennung von Delta-9-Tetrahydrocannabinol (螖9-THC) entwickelt wurden.
Die Erstlieferung umfasst 200 Breath Cartridges und mehrere BCUs. Die Unternehmen arbeiten bei der Herstellung, Vermarktung, Distribution und Logistik des MBT zusammen. Omega Laboratories, ein international f眉hrendes Labor f眉r forensische Drogentests mit ISO/IEC 17025-Akkreditierung, hat bereits ein Validation Packet f眉r ihre laborentwickelte Testmethode zur Untersuchung von Delta-9-THC-Analyt geliefert.
- None.
- Early stage of commercialization with limited initial deployment
- Success depends on market adoption and regulatory acceptance
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 鈥淐ompany or Cannabix鈥�) reports that it has delivered multiple Cannabix Marijuana Breath Test (鈥淢BT鈥�) units to Omega Laboratories Inc. of Ohio, USA (鈥淥mega Laboratories鈥� or 鈥淥mega鈥�) to initiate phased commercialization efforts. The MBT hardware includes Cannabix鈥檚 proprietary Breath Collection Unit (BCU) and Breath Cartridges (BC) technology which are designed to collect and preserve breath samples to be analysed with Omega鈥檚 Laboratory Developed Test Method to detect delta-9-tetrahydrocannabinol (螖9-THC), the primary psychoactive component of cannabis, in breath (see Figures 1 and 2). The MBT is focused on 鈥渞ecent use鈥� detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (1).
Figure 1. Cannabix Marijuana Breath Test Hardware (BCU and Breath Cartridges)
Cannabix and Omega are working together to implement the MBT with select key clients and undertake a phased ramp-up to meet demand. Furthermore, the delivery of the initial units will support the coordination and the integration of breath testing (using Cannabix Breath Cartridges) into Omega鈥檚 suite of services and lab testing protocols. The parties are working together on manufacturing, marketing, distribution, support and logistics for the MBT. With the current shipment Cannabix has delivered 200 Breath Cartridges and several BCUs.
Omega Laboratories is an international industry leader in forensic drugs of abuse testing for over twenty years. Omega has multiple federal as well as international certifications and accreditations for its world class facility and has extensive experience in novel technology for detection of drugs of abuse.
Earlier in the year, Omega delivered a Validation Packet for Omega鈥檚 Laboratory Developed Test Method to test delta9 THC analytes. The Validation Packet was performed in Omega鈥檚 ISO/IEC 17025 accredited laboratory environment utilizing their well recognized Quality Management System.
Figure 2. Sample Collection with Cannabix Breath Collection Unit
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
鈥淩av Mlait鈥�
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company鈥檚 plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company鈥檚 development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 鈥減atent pending鈥� or 鈥減rovisional patents鈥� technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement聽are available at:
FAQ
What is the Cannabix Technologies (BLOZF) Marijuana Breath Test technology?
How many MBT units did Cannabix Technologies deliver to Omega Laboratories?
What advantage does the Cannabix breath test have over other testing methods?
Who is Omega Laboratories and what is their role in the BLOZF breath test deployment?
What is the current stage of Cannabix Technologies' MBT commercialization?
